Trial Profile
A observational clinical study of Apatinib combined chemotherapy in the treatment of gastric cancer with AFP positive
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 07 Feb 2017 Planned number of patients changed from 30 to 16.
- 28 Apr 2016 New trial record